Cargando…

Comparative effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in non-hospitalised high-risk patients during Omicron waves: observational cohort study using the OpenSAFELY platform

BACKGROUND: Timely evidence of the comparative effectiveness between COVID-19 therapies in real-world settings is needed to inform clinical care. This study aimed to compare the effectiveness of nirmatrelvir/ritonavir versus sotrovimab and molnupiravir in preventing severe COVID-19 outcomes in non-h...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zheng, Bang, Tazare, John, Nab, Linda, Green, Amelia CA., Curtis, Helen J., Mahalingasivam, Viyaasan, Herrett, Emily L., Costello, Ruth E., Eggo, Rosalind M., Speed, Victoria, Bacon, Sebastian CJ., Bates, Christopher, Parry, John, Cockburn, Jonathan, Hester, Frank, Harper, Sam, Schaffer, Andrea L., Hulme, William J., Mehrkar, Amir, Evans, Stephen JW., MacKenna, Brian, Goldacre, Ben, Douglas, Ian J., Tomlinson, Laurie A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624988/ https://www.ncbi.nlm.nih.gov/pubmed/37927438 http://dx.doi.org/10.1016/j.lanepe.2023.100741

Ejemplares similares

Comparative effectiveness of sotrovimab and molnupiravir for prevention of severe covid-19 outcomes in patients in the community: observational cohort study with the OpenSAFELY platform
por: Zheng, Bang, et al.
Publicado: (2022)

Comparative effectiveness of sotrovimab and molnupiravir for preventing severe COVID-19 outcomes in patients on kidney replacement therapy: observational study using the OpenSAFELY-UKRR and SRR databases
por: Zheng, Bang, et al.
Publicado: (2023)

OpenSAFELY: Representativeness of electronic health record platform OpenSAFELY-TPP data compared to the population of England
por: Andrews, Colm, et al.
Publicado: (2022)

First dose COVID-19 vaccine coverage amongst adolescents and children in England: an analysis of 3.21 million patients' primary care records in situ using OpenSAFELY
por: Hopcroft, Lisa E., et al.
Publicado: (2023)

Factors associated with COVID-19 vaccine uptake in people with kidney disease: an OpenSAFELY cohort study
por: Parker, Edward PK, et al.
Publicado: (2023)

Comparative effectiveness of two- and three-dose COVID-19 vaccination schedules involving AZD1222 and BNT162b2 in people with kidney disease: a linked OpenSAFELY and UK Renal Registry cohort study
por: Parker, Edward P.K., et al.
Publicado: (2023)

Incidence of Viral Rebound After Treatment With Nirmatrelvir-Ritonavir and Molnupiravir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2022)

Protocol for an OpenSAFELY cohort study collecting patient-reported outcome measures using the TPP Airmid smartphone application and linked big data to quantify the health and economic costs of long COVID (OpenPROMPT)
por: Herrett, Emily, et al.
Publicado: (2023)

Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY
por: Green, Amelia, et al.
Publicado: (2022)

Efficacy of Sotrovimab (SOT), Molnupiravir (MOL), and Nirmatrelvir/Ritponavir (N/R) and Tolerability of Molnupiravir in Outpatients at High Risk for Severe COVID-19
por: Kauer, Victoria, et al.
Publicado: (2023)

Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study
por: Evans, Andrew, et al.
Publicado: (2023)

Molnupiravir, Nirmatrelvir/Ritonavir, or Sotrovimab for High-Risk COVID-19 Patients Infected by the Omicron Variant: Hospitalization, Mortality, and Time until Negative Swab Test in Real Life
por: Cegolon, Luca, et al.
Publicado: (2023)

New Perspectives on Antimicrobial Agents: Molnupiravir and Nirmatrelvir/Ritonavir for Treatment of COVID-19
por: Atmar, Robert L., et al.
Publicado: (2022)

Molnupiravir and Nirmatrelvir/Ritonavir: Tolerability, Safety, and Adherence in a Retrospective Cohort Study
por: Mazzitelli, Maria, et al.
Publicado: (2023)

Minimal Risk of Drug-Induced Liver Injury With Molnupiravir and Ritonavir-Boosted Nirmatrelvir
por: Wong, Grace Lai-Hung, et al.
Publicado: (2023)

Overall and cause-specific hospitalisation and death after COVID-19 hospitalisation in England: A cohort study using linked primary care, secondary care, and death registration data in the OpenSAFELY platform
por: Bhaskaran, Krishnan, et al.
Publicado: (2022)

OpenSAFELY: impact of national guidance on switching anticoagulant therapy during COVID-19 pandemic
por: Curtis, Helen J, et al.
Publicado: (2021)

Identifying Care Home Residents in Electronic Health Records - An OpenSAFELY Short Data Report
por: Schultze, Anna, et al.
Publicado: (2021)

Molnupiravir and nirmatrelvir–ritonavir reduce mortality risk during post-acute COVID-19 phase()
por: Wan, Eric Yuk Fai, et al.
Publicado: (2023)

547. Molnupiravir and Nirmatrelvir/Ritonavir Effectiveness in Reducing the Risk for COVID-19 Disease Progression and Death
por: Paraskevis, Dimitrios, et al.
Publicado: (2023)

Risks of covid-19 hospital admission and death for people with learning disability: population based cohort study using the OpenSAFELY platform
por: Williamson, Elizabeth J, et al.
Publicado: (2021)

Nirmatrelvir/Ritonavir and Molnupiravir in the Treatment of Mild/Moderate COVID-19: Results of a Real-Life Study
por: Gentile, Ivan, et al.
Publicado: (2022)

Comparing molnupiravir and nirmatrelvir/ritonavir efficacy and the effects on SARS-CoV-2 transmission in animal models
por: Cox, Robert M., et al.
Publicado: (2023)

514. Nirmatrelvir/ritonavir or Molnupiravir for Treatment of Non-hospitalized Patients with COVID-19 at Risk of Disease Progression
por: Butt, Adeel A, et al.
Publicado: (2023)

Trends, variation, and clinical characteristics of recipients of antiviral drugs and neutralising monoclonal antibodies for covid-19 in community settings: retrospective, descriptive cohort study of 23.4 million people in OpenSAFELY
por: Green, Amelia C A, et al.
Publicado: (2023)

Association between household composition and severe COVID-19 outcomes in older people by ethnicity: an observational cohort study using the OpenSAFELY platform
por: Wing, Kevin, et al.
Publicado: (2022)

Healthcare in England was affected by the COVID-19 pandemic across the pancreatic cancer pathway: A cohort study using OpenSAFELY-TPP
por: Lemanska, Agnieszka, et al.
Publicado: (2023)

Safety of COVID-19 vaccination and acute neurological events: A self-controlled case series in England using the OpenSAFELY platform
por: Walker, Jemma L, et al.
Publicado: (2022)

Rates of serious clinical outcomes in survivors of hospitalisation with COVID-19 in England: a descriptive cohort study within the OpenSAFELY platform
por: Tazare, John, et al.
Publicado: (2022)

A national audit of pancreatic enzyme prescribing in pancreatic cancer from 2015 to 2023 in England using OpenSAFELY-TPP
por: Lemanska, Agnieszka, et al.
Publicado: (2023)

Comparison of methods for predicting COVID-19-related death in the general population using the OpenSAFELY platform
por: Williamson, Elizabeth J., et al.
Publicado: (2022)

HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
por: Bhaskaran, Krishnan, et al.
Publicado: (2021)

Clinical Outcomes Following Treatment for COVID-19 With Nirmatrelvir/Ritonavir and Molnupiravir Among Patients Living in Nursing Homes
por: Ma, Bosco Hon-Ming, et al.
Publicado: (2023)

Association of Molnupiravir and Nirmatrelvir-Ritonavir with reduced mortality and sepsis in hospitalized omicron patients: a territory-wide study
por: Wai, Abraham Ka-chung, et al.
Publicado: (2023)

Clinical characteristics of COVID-19 rebound after nirmatrelvir-ritonavir or molnupiravir therapy: A prospective cohort study
por: Han, Jaijun, et al.
Publicado: (2023)

Ethnic differences in the indirect effects of the COVID-19 pandemic on clinical monitoring and hospitalisations for non-COVID conditions in England: a population-based, observational cohort study using the OpenSAFELY platform
por: Costello, Ruth E., et al.
Publicado: (2023)

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19
por: Baldi, Federico, et al.
Publicado: (2023)

OpenSAFELY: factors associated with COVID-19 death in 17 million patients
por: Williamson, Elizabeth J, et al.
Publicado: (2020)

Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts
por: Wong, Angel YS, et al.
Publicado: (2021)

Factors associated with deaths due to COVID-19 versus other causes: population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform
por: Bhaskaran, Krishnan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_k9ohn93hf0ht0fjudo49tt361u